Please assess the completion status of the following clinical trial:

Trial Title: I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male aged 50 to 80 years~* Subjects who meet the NIA-AA core clinical criteria for probable Alzheimer's disease dementia~* Clinical Dementia Rating (CDR) score of 0.5 or more and MMSE ≥ 17~* Subjects on acetylcholinesterase inhibitor or memantine therapy for Alzheimer's disease must be on a stable dose prior to baseline~* Subjects must have partners/caregivers able to accompany them during the study visits, as well as monitor for, and report, any adverse events to the study team in the week after scanning~* Non-smoker~* Willing to comply with protocol and lifestyle restrictions~* Excellent understanding of English (for questionnaires)~* Participant is ambulant and capable of attending a PET scan visit as an outpatient.~* Participants with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 7.5.1. This criterion must be followed from after the first PET Scan until after the follow-up contact.~* Adequate collateral flow to the radial and ulnar arteries in both hands as determined by an Allen's test.~* Body weight ≥50 kg.~Exclusion Criteria:~* Current or past history of major psychiatric disorder~* Current or past history of substance use disorder~* Clinically significant brain injury or abnormality~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).~* History of or suffers from claustrophobia or subject feels unable to lie flat and still on their back for a period of up to 2 hours in the PET/CT scanner.~* Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations or occupational exposure resulting in radiation exposure greater than 10 mSv over the past 3 years or greater than 10 mSv in a single year including the proposed study. Clinical exposure from which the subject receives a direct benefit is not included in these calculations.~* Previous inclusion in a research and/or medical protocol involving study medication within the last 3 months~* In the opinion of the study team they are unlikely to comply with the study protocol and restrictions that it imposes.~* Contraindications for subjects undergoing an MR scan (including but not limited to metal implants pacemakers, etc.)

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patient Group (Type: EXPERIMENTAL): Baseline PET scan followed by a blocked PET scan

Based on this trial design, predict the completion outcome and termination type (if applicable).